Season Finale: Dabigatran Reversal and Digoxin Mortality

Subscribe on iTunes

Fahad and Amol want you to recognize that:

1. Idarucizumab as an agent that specifically reverses the hemostatic effects of dabigatran. 

2. A post-hoc analysis of the ROCKET-AF study showed that digoxin is associated with increased mortality in patients with atrial fibrillation.

The papers

Idaracizumab for Dabigatran reversal.

Digoxin use and mortality in ROCKET-AF.

Good stuff



Screening for occult cancer in unprovoked Venous Thromboembolism.

Perioperative bridging anticoagulation in Atrial Fibrillation

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more